REV1 and neoplasm: In a study that employed the Eμ-myc arf-/- mouse model of B-cell lymphoma, when mice were subjected to repeated cycles of tumor engraftment and cyclophosphamide treatment, relapsed tumors that appeared after the first round of chemotherapy continued to respond to cyclophosphamide if they were Rev1 deficient.